Proteins are frequently modified by complex carbohydrates (glycans) that play central roles
in maintaining the structural and functional integrity of cells and tissues in humans and lower …

Quantitative abnormalities in factor VIII (FVIII) and its binding partner, von Willebrand factor
(VWF), are associated with an increased risk of bleeding or thrombosis, and pathways that …

Quantitative abnormalities of the von Willebrand factor–factor VIII (VWF-FVIII) complex
associate with inherited bleeding or thrombotic disorders. Receptor-mediated interactions …

In hemophilia A, the most severe complication of factor VIII (FVIII) replacement therapy
involves the formation of FVIII neutralizing antibodies, also known as inhibitors, in 25% to …

Processing by the proprotein convertase furin is believed to be critical for the biological
activity of multiple proteins involved in hemostasis, including coagulation factor VIII (FVIII) …

Hemophilia A is a bleeding disorder characterized by the absence or dysfunction of blood
coagulation factor VIII (FVIII). Patients are treated with regular infusions of FVIII concentrate …

Chronic kidney disease (CKD) affects 30 million Americans and is associated with
approximately a two-fold increased risk of venous thromboembolism (VTE). There is a …

The immunogenicity of therapeutic factor VIII (FVIII) in patients with hemophilia A has been
puzzling scientific and clinical communities for more than 3 decades. Indeed, the …

Nonsevere hemophilia A (NSHA) is an inherited X-linked bleeding disorder, caused by
mutations of the F8 gene, leading to decreases of clotting factor VIII (FVIII) levels to 1 to 40 …

A major complication in treating hemophilia A is the development of neutralizing antibodies
(inhibitors) against therapeutic administered factor VIII (FVIII), which occurs in approximately …